Table 1 Trends in RDT-determined diagnostic positivity (DP) at each cluster over time as different IRS treatments were applied
Cluster | October 2010–March 2011 | October 2011–March 2012 | October 2012–March 2013 | |||
|---|---|---|---|---|---|---|
IRS treatment | DPÂ % (n/N) | IRS treatment | DPÂ % (n/N) | IRS treatment | DPÂ % (n/N) | |
1 | None | 24.7 (372/1508) | None | 9.5 (95/998) | None | 14.4 (150/1039) |
2 | None | 20.9 (559/2676) | Pirimiphosmethyl EC | 8.5 (280/3292) | None | 11.9 (126/1061) |
3 | None | 26.9 (809/3006) | None | 10.8 (436/4033) | None | 14.1 (282/2004) |
4 | Deltamethrin WG | 33.2 (825/2489) | Pirimiphosmethyl EC | 5.9 (217/3708) | Pirimiphosmethyl EC | 10.8 (314/2908) |
5 | Deltamethrin WG | 27.5 (396/1439) | Pirimiphosmethyl EC | 18.2 (624/3436) | Pirimiphosmethyl EC | 27.3 (456/1673) |
6 | Deltamethrin WG | 11.9 (338/2845) | Lambdacyhalothrin CS | 5.2 (76/1457) | Lambdacyhalothrin CS | 3.8 (57/1505) |
7 | Deltamethrin WG | 6.0 (144/2415) | Lambdacyhalothrin CS | 4.2 (130/3111) | Lambdacyhalothrin CS | 2.99 (33/1105) |
8 | None | 55.7 (202/363) | None | 29.9 (974/3261) | Pirimiphosmethyl CS | 9.0 (209/2321) |
9 | None | 36.4 (4/11) | Pirimiphosmethyl EC | 46.6 (684/1467) | Pirimiphosmethyl CS | 23.5 (366/1561) |
10 | None | 50.7 (172/339) | None | 35.4 (444/1254) | Pirimiphosmethyl CS | 27.1 (363/1341) |
11 | None | 51.3 (60/117) | Pirimiphosmethyl EC | 30.2 (941/3112) | None | 11.9 (300/2531) |
12 | None | 61.9 (26/42) | None | 33.9 (514/1517) | Pirimiphosmethyl CS | 21.7 (246/1132) |
13 | None | 60.0 (120/200) | Pirimiphosmethyl EC | 27 (5.033/1974) | None | 30.6 (666/2180) |
14 | None | 52.4 (33/63) | None | 41.3 (786/1904) | Pirimiphosmethyl CS | 16.99 (221/1301) |